Prostatic Cancer Clinical Trial
Official title:
A Phase I/IIa Study of Autologous Cell-based Vaccine Therapy With CreaVax-PC in Hormone-Refractory Metastatic Prostate Cancer Patients With PSA Relapse to Evaluate the Safety and Efficacy
This is an open label, Phase I/IIa trial of immunotherapy with CreaVax-PC as treatment in men with hormone-Refractory Metastatic Prostate Cancer.
CreaVax-PC consisted of antigen (PSA, PAP and KLH) primed dendritic cell is an
investigational product designed to activate a man's immune response, so they can detect
prostate cancer cells and initiate an immune response against prostate cancer antigens.
If patients decide to participate and are eligible, they will be enrolled in the study and
will receive active product (CreaVax-PC). In detail, patients will receive CreaVax-PC
injection at intervals of 3 weeks, maximum 6 times during 21 weeks. PSA increase rate is a
primary evaluation variables and tumor suppression effect is secondary evaluation variables.
We also evaluate time to progression, overall survival and immune response.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT05191017 -
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
|
Phase 1/Phase 2 | |
| Completed |
NCT00970203 -
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
|
Phase 2 | |
| Completed |
NCT01086956 -
Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy
|
N/A | |
| Completed |
NCT00643617 -
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
|
N/A | |
| Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02687308 -
Open Anterograde Radical Prostatectomy Compared to Open Retrograde Technique
|
N/A | |
| Completed |
NCT01284608 -
Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)
|
N/A | |
| Completed |
NCT04421781 -
Salvage HIFU for Local Recurrence in the Prostatic Bed After Prostatectomy and External Beam Radiation Therapy : Preliminary Results
|
||
| Recruiting |
NCT05740956 -
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Enrolling by invitation |
NCT03173924 -
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05851521 -
To Evaluate LUTS and Complications Between Indwelling Catheter and Temporary Prostatic Stent in Patients Undergoing Minimally Invasive Procedures for the Treatment of Localized Prostate Cancer or Benign Prostatic Hyperplasia (HERMES)
|
N/A | |
| Completed |
NCT01998685 -
Prothrombotic Factors and Anaesthesia in Prostate Cancer
|
N/A | |
| Completed |
NCT01477749 -
Sipuleucel-T Manufacturing Demonstration Study
|
Phase 2 | |
| Terminated |
NCT03606889 -
Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-prostatectomy Analgesia
|
N/A | |
| Completed |
NCT03481816 -
Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
|
Phase 1 | |
| Recruiting |
NCT05623878 -
68Ga-labeled NY108 PET Imaging in Patients
|
Early Phase 1 | |
| Not yet recruiting |
NCT05184790 -
LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology
|
||
| Completed |
NCT02564120 -
North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)
|
||
| Active, not recruiting |
NCT01787630 -
To Evaluate the Technique and Effects of Separating the Prostate and Rectum With Hyaluronic Acid During Radiotherapy
|
Phase 2/Phase 3 | |
| Terminated |
NCT02349139 -
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
|
Phase 1 |